SciBase Announces New Share Issue to Raise Funds for Growth in U.S. Market

SciBase Expands Through Directed Share Issue

SciBase Holding AB (publ), a prominent player in the medical technology sector, has recently disclosed a significant financial move aimed at strengthening its market presence. On June 23, 2025, the company’s board of directors announced a directed share issue, aimed at raising approximately SEK 11 million. This initiative aligns with the company's broader strategic goals released on June 16th, and it follows a similar prior capital raise undertaken for approximately SEK 19 million in the previous week.

The recent share issue is specifically directed towards Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS, and Ribbskottet AB, with the objective of financing critical aspects of the business. This includes bolstering the commercialization of SciBase's flagship product, Nevisense, particularly in the rapidly growing U.S. dermatology market.

Unraveling SciBase’s Mission and Technology

SciBase is dedicated to revolutionizing dermatology through early detection and prevention of skin diseases using advanced technologies. The company’s core product, Nevisense, integrates artificial intelligence and electrical impedance spectroscopy (EIS) to enhance diagnostic precision, particularly for conditions like melanoma. This innovative approach allows healthcare providers to identify skin diseases more swiftly, ultimately improving patient outcomes.

In 2024, SciBase struck remarkable sales growth in the American market, witnessing a staggering 177% increase year-over-year. Quarterly figures were even more impressive, with a 306% increase noted in sales from the first quarter of 2025 compared to the same timeframe in 2024. Such figures illustrate the soaring demand and confidence in the Nevisense technology, which has positioned SciBase as a leader in the dermatological technology space.

To further build on this momentum, SciBase has made strides in establishing trust among key opinion leaders (KOLs) in the U.S., a vital element of their marketing strategy. The company published a consensus report in collaboration with various KOLs in 2024, highlighting Nevisense’s efficacy in improving diagnostic assessments. Furthermore, SciBase is working diligently to secure reimbursement from insurance providers, aiming to incorporate EIS technology within clinical guidelines for dermatology.

Strategic Investments in R&D and Partnerships

SciBase is not only focused on its existing products but is also dedicated to expanding its research and development capabilities. With fresh funds from the recent share issue, the company plans to invest in the development of new products, particularly targeting atopic dermatitis, another growing concern in dermatology.

A recent collaboration with Castle Biosciences aims to advance diagnostic tests within dermatological fields. This partnership is set to explore the potential for developing tools that predict flare-ups in patients suffering from atopic dermatitis, thereby enhancing patient care through tailored interventions.

Financial Overview of the Directed Issues

Through the proposed share issue, SciBase aims to boost its capital base, increasing its total shares by a maximum of 75,886,950, elevating total shares from 338,295,633 to 414,182,583. This initiative represents an increase in share capital by SEK 3,794,347.50. However, this proactive measure also entails a dilution of approximately 18.3% for existing shareholders, a factor that has been carefully considered by the board amid discussions regarding the necessity and timing of the capital raise.

Despite the potential risks, the decision to deviate from existing shareholders' preferential rights in executing this share issue stems from consultations with larger investors, indicating a need for immediate action in a fluctuating market environment. The advantages of swift execution in this capital raise over a more resource-intensive rights issue influenced the board's decision.

Conclusion

As SciBase forges ahead with its expansion strategy, it emphasizes its commitment to transforming dermatological care through innovative technology. The recent directed share issue reflects both determination to capture market opportunities and the necessity of maintaining a competitive edge in a challenging landscape. By leveraging these funds, the company aims not only to enhance its product offerings but also to positively impact patient outcomes across the globe.

For further updates, investors and stakeholders are encouraged to stay connected as SciBase progresses through its upcoming initiatives and financial strategies.